Movano Evie Ring Could Soon Get FDA Clearance, Analyst Says: 'A Validated Wearable Device Truly Opens The Market'
Portfolio Pulse from Priya Nigam
Movano Inc (NASDAQ:MOVE) is expected to receive FDA clearance for its Evie ring this quarter, with a full commercial launch likely later this year. Analyst Bruce Jackson initiated coverage with a Speculative Buy rating and a price target of $2.00. The Evie ring aims to provide medical-grade data and has already shown promising sales during a soft launch.
July 30, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Movano Inc is expected to receive FDA clearance for its Evie ring this quarter, with a full commercial launch likely later this year. Analyst Bruce Jackson initiated coverage with a Speculative Buy rating and a price target of $2.00. The Evie ring aims to provide medical-grade data and has already shown promising sales during a soft launch.
The FDA clearance and subsequent commercial launch of the Evie ring are significant milestones for Movano Inc. The analyst's Speculative Buy rating and $2.00 price target indicate positive sentiment. The initial sales figures from the soft launch also suggest strong market potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100